Karuna Therapeutics Announces Leadership Appointments
03 Août 2023 - 12:30PM
Business Wire
Jonathan Rosin appointed to Chief Human
Resources Officer
Jason Brown promoted to Chief Financial
Officer
Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage
biopharmaceutical company driven to create and deliver
transformative medicines for people living with psychiatric and
neurological conditions, today announced the appointment of
Jonathan Rosin to Chief Human Resources Officer (CHRO) and the
promotion of Jason Brown to Chief Financial Officer (CFO). Mr.
Brown succeeds Troy Ignelzi, who will remain at Karuna for a
transition period through the end of the third quarter of 2023.
“These executive appointments are a key part of our transition
to a fully integrated organization comprised of leaders who have
the skills, experience, and judgement needed to execute on our
mission,” said Bill Meury, president and chief executive officer of
Karuna Therapeutics. “Jonathan is a proven human resource leader
who has extensive experience growing highly effective
growth-oriented teams and cultures.”
Mr. Rosin brings more than 30 years of experience in human
resources, organizational development, and talent management. Prior
to Karuna, he was the CHRO of Wave Life Sciences, where he was
responsible for leading the company’s human resource strategy and
organizational development. Prior to joining Wave, Mr. Rosin served
as CHRO at Ironwood Pharmaceuticals, where he was instrumental in
building organizational capabilities and shaping the company’s
culture to support its transition to a fully integrated
biopharmaceutical company. Prior to Ironwood, he held management
and leadership development roles at Fidelity Investments and Sanofi
Genzyme. Mr. Rosin received his bachelor’s degree in psychology and
his master’s degree in clinical psychology from the University of
Cape Town, South Africa.
“Over the past five years, Jason has been an integral leader in
our organization, and is known and respected for his
detail-oriented and forward-thinking mindset,” commented Mr. Meury.
“He has extensive knowledge of and experience with all aspects of
the finance function – including balance sheet and treasury
management, financial planning and analysis, and business
development transactions – which will be invaluable as we continue
to grow our organization and internal capabilities. With a strong
balance sheet and an anticipated commercial launch in the second
half of 2024, the promotion of Jason to CFO is a logical and timely
next step.”
Mr. Brown currently serves as Senior Vice President, Finance, at
Karuna, where he is responsible for overseeing finance, accounting,
treasury, procurement, and business development transactions. He
joined Karuna in 2018 as Vice President, Finance. Prior to this, he
worked at PureTech Health in corporate finance and at Novartis in
FP&A. Mr. Brown has a bachelor’s degree in economics from
Hamilton College and an MBA from Boston College.
“On behalf of Karuna, we’d like to thank Troy for his commitment
and contributions over the past four years,” said Mr. Meury. “He
has been a key member of the leadership team and instrumental in
the growth of Karuna – from our IPO and multiple successful equity
financings to building our core finance capabilities – all of which
have contributed to a strong foundation for the company.”
About Karuna Therapeutics
Karuna Therapeutics is a clinical-stage biopharmaceutical
company driven to create and deliver transformative medicines for
people living with psychiatric and neurological conditions. At
Karuna, we understand there is a need for differentiated and more
effective treatments that can help patients navigate the challenges
presented by these severe and disabling disorders. Utilizing our
extensive knowledge of neuroscience, we are harnessing the untapped
potential of the brain in pursuit of novel pathways to develop
medicines that make meaningful differences in peoples’ lives. For
more information, please visit www.karunatx.com.
Forward Looking Statements
This press release contains forward looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, including statements regarding our expectations about the
timing of our regulatory filings, our goals to develop and
commercialize our product candidates, our liquidity and capital
resources and other statements identified by words such as “could,”
“expects,” “intends,” “may,” “plans,” “potential,” “should,”
“will,” “would,” or similar expressions and the negatives of those
terms. Forward looking statements are not promises or guarantees of
future performance, and are subject to a variety of risks and
uncertainties, many of which are beyond our control, and which
could cause actual results to differ materially from those
contemplated in such forward-looking statements. These factors
include risks related to our limited operating history, our ability
to obtain necessary funding, and other risks inherent in clinical
development, the timing and scope of regulatory approvals, changes
in laws and regulations to which we are subject, , and other risks
set forth under the heading “Risk Factors” of our Annual Report on
Form 10-K for the year ended December 31, 2022 and in our
subsequent filings with the Securities and Exchange Commission. Our
actual results could differ materially from the results described
in or implied by such forward looking statements. Forward-looking
statements speak only as of the date hereof, and, except as
required by law, we undertake no obligation to update or revise
these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230803225967/en/
Investors: Alexis Smith +1 (518) 338-8990
asmith@karunatx.com
Karuna Therapeutics (NASDAQ:KRTX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Karuna Therapeutics (NASDAQ:KRTX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024